The Experts below are selected from a list of 7338 Experts worldwide ranked by ideXlab platform
Bruce Barrett - One of the best experts on this subject based on the ideXlab platform.
-
Echinacea for Preventing and Treating the Common Cold
JAMA, 2015Co-Authors: Marlies Karsch-völk, Bruce Barrett, K LindeAbstract:Clinical Question Are Echinacea products associated with a reduced incidence and a shorter duration of common colds compared with placebo? Bottom Line Individual prophylaxis trials show no association with prevention of the common cold, but exploratory meta-analysis suggests that Echinacea products may be associated with a small reduction in cold incidence. In treatment trials, there was no association of Echinacea products with a shorter duration of colds.
-
Echinacea for Treating the Common Cold: A Randomized Trial
Annals of internal medicine, 2010Co-Authors: Bruce Barrett, Kerry Bone, Roger L. Brown, Dave Rakel, Marlon P. Mundt, Shari Barlow, Tola EwersAbstract:Background Echinacea is widely used to treat the common cold. Objective To assess the potential benefits of Echinacea as a treatment of common cold. Design Randomized, controlled trial. (ClinicalTrials.gov registration number: NCT00065715) Setting Dane County, Wisconsin. Patients 719 patients, aged 12 to 80 years, with new-onset common cold. Intervention Patients were assigned to 1 of 4 parallel groups: no pills, placebo pills (blinded), Echinacea pills (blinded), or Echinacea pills (unblinded, open-label). Echinacea groups received the equivalent of 10.2 g of dried Echinacea root during the first 24 hours and 5.1 g during each of the next 4 days. Indistinguishable placebo tablets contained only inert ingredients. Measurements The primary outcome was the area under the curve for global severity, with severity assessed twice daily by self-report using the Wisconsin Upper Respiratory Symptom Survey, short version. Secondary outcomes included interleukin-8 levels and neutrophil counts from nasal wash, assessed at intake and 2 days later. Results Of the 719 patients enrolled, 713 completed the protocol. Mean age was 33.7 years, 64% were female, and 88% were white. Mean global severity was 236 and 258 for the blinded and unblinded Echinacea groups, respectively; 264 for the blinded placebo group; and 286 for the no-pill group. A comparison of the 2 blinded groups showed a 28-point trend (95% CI, -69 to 13 points) toward benefit for Echinacea (P = 0.089). Mean illness duration in the blinded and unblinded Echinacea groups was 6.34 and 6.76 days, respectively, compared with 6.87 days in the blinded placebo group and 7.03 days in the no-pill group. A comparison of the blinded groups showed a nonsignificant 0.53-day (CI, -1.25 to 0.19 days) benefit (P = 0.075). Median change in interleukin-8 levels and neutrophil counts were also not statistically significant (30 ng/L and 1 cell/high-power field [hpf] in the no-pill group, 39 ng/L and 1 cell/hpf in the blinded placebo group, 58 ng/L and 2 cells/hpf in the blinded Echinacea group, and 70 ng/L and 1 cell/hpf in the open-label Echinacea group). Limitation Higher-than-expected variability limited power to detect small benefits. Conclusion Illness duration and severity were not statistically significant with Echinacea compared with placebo. These results do not support the ability of this dose of the Echinacea formulation to substantively change the course of the common cold. Primary funding source National Center for Complementary and Alternative Medicine, National Institutes of Health.
-
treatment of the common cold with unrefined Echinacea a randomized double blind placebo controlled trial
Annals of Internal Medicine, 2002Co-Authors: Bruce Barrett, Roger L. Brown, Kristin Locken, Rob Maberry, James A Bobula, Donn DalessioAbstract:Background: Echinacea preparations are widely used to treat the common cold. Objective: To assess the efficacy of dried, encapsulated, whole-plant Echinacea as early treatment for the common cold. Design: Randomized, double-blind, placebo-controlled community-based trial. Setting: University of Wisconsin-Madison, Madison, Wisconsin. Participants: 148 registered students with common colds of recent onset. Intervention: An encapsulated mixture of unrefined Echinacea purpurea herb (25%) and root (25%) and E. angustifolia root (50%) taken in 1-g doses six times on the first day of illness and three times on each subsequent day of illness for a maximum of 10 days. Measurements: Severity and duration of self-reported symptoms of upper respiratory tract infection. Results: No statistically significant differences were detected between the Echinacea and placebo groups for any of the measured outcomes. Trajectories of severity over time were nearly identical in the two groups. Mean cold duration was 6.01 days in both groups as a whole, 5.75 days in the placebo group, and 6.27 days in the Echinacea group (between-group difference, -0.52 day [95% Cl, -1.09 to 0.22 days]). After controlling for severity and duration of symptoms before study entry, sex, date of enrollment, and use of nonprotocol medications, researchers found no statistically significant treatment effect (adjusted hazard ratio, 1.24 [Cl, 0.86 to 1.78]). Multivariable regression models assessing severity scores over time failed to detect statistically significant differences between the Echinacea and placebo groups. Conclusion: Compared with placebo, unrefined Echinacea provided no detectable benefit or harm in these college students who had the common cold.
Trifone D’addabbo - One of the best experts on this subject based on the ideXlab platform.
-
Nematicidal activity of Echinacea species on the root-knot nematode Meloidogyne incognita
Journal of Pest Science, 2020Co-Authors: Sebastiano Laquale, Pinarosa Avato, Maria Pia Argentieri, Vincenzo Candido, Michele Perniola, Trifone D’addabboAbstract:Echinacea species are reported for a large content of bioactive compounds, but their effects on phytoparasitic nematodes are still unknown. This study comparatively investigated the in vitro activity of chemically characterized extracts from E. angustifolia , E. pallida and E. purpurea on juveniles and eggs of the root-knot nematode Meloidogyne incognita . Suppressiveness of soil amendments with Echinacea plant biomasses was also investigated against M. incognita on tomato in potting mixes. More than 50% juvenile mortality occurred after a 48-h exposure to a 500 µg mL^−1 solution of all Echinacea extracts, as well as more than 50% of M. incognita eggs did not hatch after a 1-week exposure to the same concentration of E. angustifolia extracts. Nematode multiplication on tomato roots was always significantly reduced in soil amended with all Echinacea biomasses, as well as almost all treatments also resulted in a significant tomato growth increase. Polar compounds such as echinacoside and chicoric acid were the main components of the extracts from Echinacea aerial parts, whereas apolar components as alkamides prevailed in root extracts. Data confirmed the potential of the three Echinacea species, mainly E. angustifolia , for the formulation of new formulates for a sustainable nematode management.
Donn Dalessio - One of the best experts on this subject based on the ideXlab platform.
-
treatment of the common cold with unrefined Echinacea a randomized double blind placebo controlled trial
Annals of Internal Medicine, 2002Co-Authors: Bruce Barrett, Roger L. Brown, Kristin Locken, Rob Maberry, James A Bobula, Donn DalessioAbstract:Background: Echinacea preparations are widely used to treat the common cold. Objective: To assess the efficacy of dried, encapsulated, whole-plant Echinacea as early treatment for the common cold. Design: Randomized, double-blind, placebo-controlled community-based trial. Setting: University of Wisconsin-Madison, Madison, Wisconsin. Participants: 148 registered students with common colds of recent onset. Intervention: An encapsulated mixture of unrefined Echinacea purpurea herb (25%) and root (25%) and E. angustifolia root (50%) taken in 1-g doses six times on the first day of illness and three times on each subsequent day of illness for a maximum of 10 days. Measurements: Severity and duration of self-reported symptoms of upper respiratory tract infection. Results: No statistically significant differences were detected between the Echinacea and placebo groups for any of the measured outcomes. Trajectories of severity over time were nearly identical in the two groups. Mean cold duration was 6.01 days in both groups as a whole, 5.75 days in the placebo group, and 6.27 days in the Echinacea group (between-group difference, -0.52 day [95% Cl, -1.09 to 0.22 days]). After controlling for severity and duration of symptoms before study entry, sex, date of enrollment, and use of nonprotocol medications, researchers found no statistically significant treatment effect (adjusted hazard ratio, 1.24 [Cl, 0.86 to 1.78]). Multivariable regression models assessing severity scores over time failed to detect statistically significant differences between the Echinacea and placebo groups. Conclusion: Compared with placebo, unrefined Echinacea provided no detectable benefit or harm in these college students who had the common cold.
Arnold S. Monto - One of the best experts on this subject based on the ideXlab platform.
-
Echinacea purpurea for Prevention of Experimental Rhinovirus Colds
Clinical Infectious Diseases, 2004Co-Authors: Steven J Sperber, Leena P. Shah, Thomas W. Ritchey, Richard D. Gilbert, Arnold S. MontoAbstract:A randomized, double-blind, placebo-controlled clinical trial was conducted to evaluate the ability of Echinacea purpurea to prevent infection with rhinovirus type 39 (RV-39). Forty-eight previously healthy adults received Echinacea or placebo, 2.5 mL 3 times per day, for 7 days before and 7 days after intranasal inoculation with RV-39. Symptoms were assessed to evaluate clinical illness. Viral culture and serologic studies were performed to evaluate the presence of rhinovirus infection. A total of 92% of Echinacea recipients and 95% of placebo recipients were infected. Colds developed in 58% of Echinacea recipients and 82% of placebo recipients (P = .114, by Fisher's exact test). Administration of Echinacea before and after exposure to rhinovirus did not decrease the rate of infection; however, because of the small sample size, statistical hypothesis testing had relatively poor power to detect statistically significant differences in the frequency and severity of illness.
Roger L. Brown - One of the best experts on this subject based on the ideXlab platform.
-
Echinacea for Treating the Common Cold: A Randomized Trial
Annals of internal medicine, 2010Co-Authors: Bruce Barrett, Kerry Bone, Roger L. Brown, Dave Rakel, Marlon P. Mundt, Shari Barlow, Tola EwersAbstract:Background Echinacea is widely used to treat the common cold. Objective To assess the potential benefits of Echinacea as a treatment of common cold. Design Randomized, controlled trial. (ClinicalTrials.gov registration number: NCT00065715) Setting Dane County, Wisconsin. Patients 719 patients, aged 12 to 80 years, with new-onset common cold. Intervention Patients were assigned to 1 of 4 parallel groups: no pills, placebo pills (blinded), Echinacea pills (blinded), or Echinacea pills (unblinded, open-label). Echinacea groups received the equivalent of 10.2 g of dried Echinacea root during the first 24 hours and 5.1 g during each of the next 4 days. Indistinguishable placebo tablets contained only inert ingredients. Measurements The primary outcome was the area under the curve for global severity, with severity assessed twice daily by self-report using the Wisconsin Upper Respiratory Symptom Survey, short version. Secondary outcomes included interleukin-8 levels and neutrophil counts from nasal wash, assessed at intake and 2 days later. Results Of the 719 patients enrolled, 713 completed the protocol. Mean age was 33.7 years, 64% were female, and 88% were white. Mean global severity was 236 and 258 for the blinded and unblinded Echinacea groups, respectively; 264 for the blinded placebo group; and 286 for the no-pill group. A comparison of the 2 blinded groups showed a 28-point trend (95% CI, -69 to 13 points) toward benefit for Echinacea (P = 0.089). Mean illness duration in the blinded and unblinded Echinacea groups was 6.34 and 6.76 days, respectively, compared with 6.87 days in the blinded placebo group and 7.03 days in the no-pill group. A comparison of the blinded groups showed a nonsignificant 0.53-day (CI, -1.25 to 0.19 days) benefit (P = 0.075). Median change in interleukin-8 levels and neutrophil counts were also not statistically significant (30 ng/L and 1 cell/high-power field [hpf] in the no-pill group, 39 ng/L and 1 cell/hpf in the blinded placebo group, 58 ng/L and 2 cells/hpf in the blinded Echinacea group, and 70 ng/L and 1 cell/hpf in the open-label Echinacea group). Limitation Higher-than-expected variability limited power to detect small benefits. Conclusion Illness duration and severity were not statistically significant with Echinacea compared with placebo. These results do not support the ability of this dose of the Echinacea formulation to substantively change the course of the common cold. Primary funding source National Center for Complementary and Alternative Medicine, National Institutes of Health.
-
treatment of the common cold with unrefined Echinacea a randomized double blind placebo controlled trial
Annals of Internal Medicine, 2002Co-Authors: Bruce Barrett, Roger L. Brown, Kristin Locken, Rob Maberry, James A Bobula, Donn DalessioAbstract:Background: Echinacea preparations are widely used to treat the common cold. Objective: To assess the efficacy of dried, encapsulated, whole-plant Echinacea as early treatment for the common cold. Design: Randomized, double-blind, placebo-controlled community-based trial. Setting: University of Wisconsin-Madison, Madison, Wisconsin. Participants: 148 registered students with common colds of recent onset. Intervention: An encapsulated mixture of unrefined Echinacea purpurea herb (25%) and root (25%) and E. angustifolia root (50%) taken in 1-g doses six times on the first day of illness and three times on each subsequent day of illness for a maximum of 10 days. Measurements: Severity and duration of self-reported symptoms of upper respiratory tract infection. Results: No statistically significant differences were detected between the Echinacea and placebo groups for any of the measured outcomes. Trajectories of severity over time were nearly identical in the two groups. Mean cold duration was 6.01 days in both groups as a whole, 5.75 days in the placebo group, and 6.27 days in the Echinacea group (between-group difference, -0.52 day [95% Cl, -1.09 to 0.22 days]). After controlling for severity and duration of symptoms before study entry, sex, date of enrollment, and use of nonprotocol medications, researchers found no statistically significant treatment effect (adjusted hazard ratio, 1.24 [Cl, 0.86 to 1.78]). Multivariable regression models assessing severity scores over time failed to detect statistically significant differences between the Echinacea and placebo groups. Conclusion: Compared with placebo, unrefined Echinacea provided no detectable benefit or harm in these college students who had the common cold.
